PRMT6 is a crucial biomarker for the progression of lung cancer, and recently developed small molecule and peptide inhibitors of PRMTs highlight the therapeutic significance of studying PRMTs, especially in high-mortality diseases such as lung cancer. This evidence concerns the gene PRMT6 and lung carcinoma.